SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion (vol 22, 550, 2021)

The requested reference [1371907c3dad7213f92f76df6e36688b0daa3060] no longer exists in our database. It has been replaced by the current reference: [0d117b07f45d0c28677eb2414cbfd1c261eb5d96]

Authors
Category Primary study
JournalTRIALS
Year 2022
This article has no abstract
Epistemonikos ID: a7df4742f47e57ba79eb736a9059cf6d3a6e9e1a
First added on: Apr 23, 2022